oa SA Pharmaceutical Journal - News

Volume 73, Issue 7
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Extracted from text ... NEWS Now you have an answer to Rotavirus! ROTARIXTM, GlaxoSmithKline's live, attenuated, human rotavirus oral vaccine, is now registered in South Africa for the prevention of rotavirus gastroenteritis. ROTARIXTM has been assessed in clinical trials involving over 63 000 infants around the world1 and has been found to be highly immunogenic*, with a favourable side-effect profile.2 ROTARIXTM prevented 85% of severe rotavirus gastroenteritis episodes and reached 100% in more severe cases.1 With regards efficacy against specific rotavirus strains, ROTARIXTM offers 91.8% efficacy against the most prevalent rotavirus strains in South Africa (G1P[8]), and significant efficacy against the less prevalent P[8] ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error